tissue plasminogen activator

(redirected from Alteplase)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for tissue plasminogen activator

a thrombolytic agent (trade name Activase) that causes fibrinolysis at the site of a blood clot

References in periodicals archive ?
Thrombolytic - alteplase was used appropriately with a good result in our patient.
Conclusions: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS).
Alteplase, or tissue plasminogen activator, is ideally given in the first three hours upon onset of acute stroke,' Tayag said at a press briefing, stressing that only patients who have an ischemic type of stroke, or those with blocked blood vessels in the brain, will benefit from the medicine since alteplase breaks down unwanted blood clots.
Keywords: alteplase, antihypertensive, blood pressure, hydralazine, ischemic stroke, labetalol, nicardipine, stroke, thrombolytic
The UK medicines watchdog wanted the benefits and risks of alteplase to be analysed after concerns were raised about its safety.
It had been suggested that giving alteplase to people with signs of early damage in the brain caused by a stroke would increase their chances of suffering a bleed on the brain, which can be fatal.
Researchers at UK-based medical journal The BMJ believe that the administration of alteplase three to four hours after a person has suffered a stroke could cause a secondary haemorrhage.
Using a novel form of crossover design, research showed that a new form of anticoagulant - alteplase - was much more successful than the cheaper heparin.
confirmed that treating stroke patients with the drug alteplase within 4.
They examined the role of plasminogen activator, which is commonly known in the UK as alteplase.
Alteplase can help reduce the disabling effects of STROKE if administered QUICKLY enough.
The more commonly administered thrombolytic agents fall under the classification of fibrin-specific thrombolytic agents, which include tissue plasminogen activators (t-PA), alteplase (Activase[R]), reteplase (Retavase[R]), and tenecteplase (TNKase[R]) (Vaishnavi et al.
However, the review of more than 3,000 patients found the drug - alteplase - offered no improvement in survival rates, the BBC reported.